Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunocompromised Patients with Protracted COVID-19: a Review of “Long Persisters”
M. Veronica Dioverti, Sonsoles Salto‐Alejandre, Ghady Haidar
Current Transplantation Reports (2022) Vol. 9, Iss. 4, pp. 209-218
Open Access | Times Cited: 56

Showing 1-25 of 56 citing articles:

Convergent Evolution in SARS-CoV-2 Spike Creates a Variant Soup from Which New COVID-19 Waves Emerge
Daniele Focosi, Rodrigo Quiroga, Scott A. McConnell, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2264-2264
Open Access | Times Cited: 117
Persistent SARS-CoV-2 infection: significance and implications
Heather Machkovech, Anne M. Hahn, Jacqueline Garonzik‐Wang, et al.
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 7, pp. e453-e462
Open Access | Times Cited: 52
SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency
Yijia Li, Manish C. Choudhary, James Regan, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 731
Open Access | Times Cited: 48
Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019
Evan M. Bloch, Daniele Focosi, Shmuel Shoham, et al.
Clinical Infectious Diseases (2023) Vol. 76, Iss. 11, pp. 2018-2024
Open Access | Times Cited: 37
Drug treatment of COVID-19 infection
Grace Lui, Giovanni Guaraldi
Current Opinion in Pulmonary Medicine (2023) Vol. 29, Iss. 3, pp. 174-183
Open Access | Times Cited: 30
Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS‐CoV‐2 infection
Zeno Pasquini, Alice Toschi, Beatrice Casadei, et al.
Hematological Oncology (2023) Vol. 41, Iss. 5, pp. 904-911
Open Access | Times Cited: 22
Respiratory infections predominate after day 100 following B-cell maturation antigen–directed CAR T-cell therapy
Jessica S Little, Megha Tandon, Joseph Hong, et al.
Blood Advances (2023) Vol. 7, Iss. 18, pp. 5485-5495
Open Access | Times Cited: 22
Persistent COVID-19 in immunocompromised patients—Israeli society of infectious diseases consensus statement on diagnosis and management
Suzy Meijer, Yael Paran, Ana Belkin, et al.
Clinical Microbiology and Infection (2024) Vol. 30, Iss. 8, pp. 1012-1017
Closed Access | Times Cited: 11
Ensitrelvir in patients with SARS-CoV-2: A retrospective chart review
Masaya Yamato, Masahiro Kinoshita, Shogo Miyazawa, et al.
Journal of Infection and Chemotherapy (2024) Vol. 30, Iss. 9, pp. 946-950
Closed Access | Times Cited: 10
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 10
Emerging viral infections in immunocompromised patients: A great challenge to better define the role of immune response
Chiara Agrati, Barbara Bartolini, Veronica Bordoni, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 20
Successful Treatment of Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Patients With Immunodeficiency With Extended Nirmatrelvir/Ritonavir: Case Series
Madison Breeden, Samuel L Aitken, Ji Hoon Baang, et al.
Open Forum Infectious Diseases (2023) Vol. 10, Iss. 4
Open Access | Times Cited: 16
Chronic COVID-19 infection in an immunosuppressed patient shows changes in lineage over time: a case report
Sheridan J.C. Baker, Landry Nfonsam, Daniela Leto, et al.
Virology Journal (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 5
Efficacy and safety of antiviral therapies for the treatment of persistent COVID-19 in immunocompromised patients since the Omicron surge: a systematic review
Caroline Hirsch, Nina Kreuzberger, Nicole Skoetz, et al.
Journal of Antimicrobial Chemotherapy (2025)
Open Access
Effectiveness and Tolerability of Dual Antiviral Therapy in Immunosuppressed Patients with Protracted SARS-CoV-2 Infection
Giovanna Travi, Francesco Peracchi, Marco Merli, et al.
Infectious Disease Reports (2025) Vol. 17, Iss. 2, pp. 17-17
Open Access
Prevention and management of infectious complications in patients with chronic lymphocytic leukemia (CLL) treated with BTK and BCL-2 inhibitors, focus on current guidelines
Małgorzata Mikulska, Chiara Oltolini, Emanuela Zappulo, et al.
Blood Reviews (2024) Vol. 65, pp. 101180-101180
Open Access | Times Cited: 4
Systemic Lupus Erythematosus and COVID-19
Μαρία Παππά, Alexandros Panagiotopoulos, Κonstantinos Thomas, et al.
Current Rheumatology Reports (2023) Vol. 25, Iss. 10, pp. 192-203
Open Access | Times Cited: 11
Successful treatment of persistent SARS-CoV-2 infection with nirmatrelvir/ritonavir plus sotrovimab in four immunocompromised patients
Massimiliano Lanzafame, Martina Gottardi, L Guella, et al.
Journal of Chemotherapy (2023) Vol. 35, Iss. 7, pp. 623-626
Closed Access | Times Cited: 10
Effectiveness of Oral Nirmatrelvir/Ritonavir vs. Intravenous Three-Day Remdesivir in Preventing Progression to Severe COVID-19: A Single-Center, Prospective, Comparative, Real-Life Study
Dimitrios Basoulis, Aristeidis Tsakanikas, Aikaterini Gkoufa, et al.
Viruses (2023) Vol. 15, Iss. 7, pp. 1515-1515
Open Access | Times Cited: 10
COVID‐19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)‐T‐cell therapy
Eleftheria Kampouri, Joshua A. Hill, M. Veronica Dioverti
Transplant Infectious Disease (2023) Vol. 25, Iss. S1
Closed Access | Times Cited: 10
Clinical outcomes and frequency of persistent infection among immunosuppressed patients treated with bebtelovimab for COVID‐19 infection at an ambulatory cancer center
Eduardo Sanchez, Elizabeth M. Krantz, Leah M. Yoke, et al.
Transplant Infectious Disease (2024) Vol. 26, Iss. 1
Closed Access | Times Cited: 3
Protecting the vulnerable: addressing the COVID-19 care needs of people with compromised immunity
Raymund R. Razonable
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Does early combination vs. Monotherapy improve clinical outcomes of clinically extremely vulnerable patients with COVID-19? Results from a retrospective propensity-weighted analysis
Maria Mazzitelli, Alberto Enrico Maraolo, Claudia Cozzolino, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 3
Therapy With Allogeneic Severe Acute Respiratory Syndrome Coronavirus-2–Specific T Cells for Persistent Coronavirus Disease 2019 in Immunocompromised Patients
Ghady Haidar, Jana L. Jacobs, Kailey Hughes Kramer, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 5, pp. 696-702
Open Access | Times Cited: 9
Immune Status and SARS-CoV-2 Viral Dynamics
Yijia Li, Carlee Moser, Evgenia Aga, et al.
The Journal of Infectious Diseases (2023) Vol. 228, Iss. Supplement_2, pp. S111-S116
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top